Wang, J., Zhang, Q., Li, H., Tong, Z., Ouyang, Q., Li, H., . . . Xu, B. Bireociclib plus fulvestrant for HR+/HER2- advanced female breast cancer progressed on or after endocrine therapy: Phase 3 BRIGHT-2 study interim analysis. Nature Portfolio.
Chicago Style (17th ed.) CitationWang, Jiayu, et al. Bireociclib Plus Fulvestrant for HR+/HER2- Advanced Female Breast Cancer Progressed on or After Endocrine Therapy: Phase 3 BRIGHT-2 Study Interim Analysis. Nature Portfolio.
MLA (9th ed.) CitationWang, Jiayu, et al. Bireociclib Plus Fulvestrant for HR+/HER2- Advanced Female Breast Cancer Progressed on or After Endocrine Therapy: Phase 3 BRIGHT-2 Study Interim Analysis. Nature Portfolio.
Warning: These citations may not always be 100% accurate.